Oxford Biomedica plc (LON:OXB)
501.00
+11.00 (2.24%)
Sep 25, 2026, 2:19 PM GMT
Oxford Biomedica Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Oxford Biomedica stock has a consensus rating of "Buy" and an average price target of 704p. The average 1-year stock price forecast is 40.42% higher than the current stock price, while the lowest is 508p (+1.40%) and the highest is 900p (+79.64%).
Price Target: 704p (+40.42%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Oxford Biomedica stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains 900p | Buy | Maintains | 900p | +79.64% | Sep 22, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Reiterates 595p | Hold | Reiterates | 595p | +18.76% | Sep 2, 2026 |
| Jefferies | Jefferies | Buy Reiterates 827p | Buy | Reiterates | 827p | +65.07% | Jun 3, 2026 |
Financial Forecast
Revenue This Year
189.35M
from 168.74M
Increased by 12.22%
Revenue Next Year
236.94M
from 189.35M
Increased by 25.13%
EPS This Year
-0.24
from -0.27
EPS Next Year
-0.06
from -0.24
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.